Axi-cel highly effective in patients with advanced non-Hodgkin lymphoma, finds Phase II trial
Investigators report 76 percent of trial participants had a complete…
Investigators report 76 percent of trial participants had a complete response to axicabtagene ciloleucel (axi-cel), despite being resistant to other therapies.